However, the International Liver Cancer Association still gave high praise to Wu Ting's experiments with negative immunomodulatory therapy and the new antiviral drug, Fengmu Tiada. They also offered a recommendation: after breaking down Wu Ting's team's research project, the antiviral and negative immunomodulatory therapies could be used as auxiliary techniques for Neutrino therapy. This, they suggested, could be a significant contribution to the international research group for HBV-related primary liver cancer.
The article concluded with a sincere invitation from Professor Edwards, welcoming Dr. Wu Ting to join the International Liver Cancer Association and the international research group for HBV-related primary liver cancer.
The moment this article was published, public opinion erupted.
Many international research teams took notice of Wu Ting's project.
